Loading...

iAnthus Capital Holdings, Inc.

IAN.CNCNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.01
CA$0.005(100.00%)

iAnthus Capital Holdings, Inc. IAN.CN Peers

See (IAN.CN) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
IAN.CNCA$0.01+100.00%33.7M-0.50-CA$0.01N/A
CURA.CNCA$5.22+9.21%4.1B-6.07-CA$0.86N/A
BHC.TOCA$9.08+2.83%3.4B-56.75-CA$0.16N/A
VRNO.CNCA$6.32+6.76%2.2B-5.40-CA$1.17N/A
GTII.CNCA$7.46+3.76%1.8B25.69CA$0.29N/A
TRUL.CNCA$5.19+7.90%1B-4.78-CA$1.08N/A
CRON.TOCA$2.61+0.38%1B13.74CA$0.19N/A
CURA.TOCA$1.15+4.55%863.4M-2.56-CA$0.45N/A
TER.CNCA$2.38-0.42%804.8M-1.33-CA$1.79N/A
DHT-UN.TOCA$13.34-0.45%745.2M333.50CA$0.04+3.92%
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

IAN.CN vs CURA.CN Comparison

IAN.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IAN.CN stands at 33.7M. In comparison, CURA.CN has a market cap of 4.1B. Regarding current trading prices, IAN.CN is priced at CA$0.01, while CURA.CN trades at CA$5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IAN.CN currently has a P/E ratio of -0.50, whereas CURA.CN's P/E ratio is -6.07. In terms of profitability, IAN.CN's ROE is +0.10%, compared to CURA.CN's ROE of -0.25%. Regarding short-term risk, IAN.CN is less volatile compared to CURA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for IAN.CN.

Stock Price Comparison

Loading...

Frequently Asked Questions

;